This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

European Pharma Law Academy
Monday 2 - Friday 6 September 2024
Downing CollegeCambridge, UK

Liliana Eskenazi
Partner at Fréget Glaser & Associés
Speaker

Profile

An accomplished EU and Competition/Antitrust Lawyer with extensive experience in both advisory work and litigation, Liliana handles complex cases before the EU and the French courts, as well as before the administrative authorities (European Commission, French Competition Authority), with a particular focus on the life sciences sector.

Well versed in all antitrust and distribution law matters, Liliana also handles multi-jurisdictional merger control cases in the context of corporate transactions.

Prior to joining Fréget Glaser & Associés in 2016, Liliana worked for eleven years in the Brussels and Paris offices of Allen & Overy LLP. She acquired significant experience in regulated sectors (pharma, energy, telecom), as well as in matters related to the interaction between intellectual property law and competition law.

Liliana Eskenazi holds a PhD in law from the University of Paris 1 - Panthéon-Sorbonne. Her thesis, L'Europe - espace de concurrence, received the Magna cum laude distinction and is published. Liliana has taught competition law at the Ecole Centrale - Supelec, and is currently lecturing at the University of Picardie and Université Paris Cité. Liliana also intervenes as a volunteer of the Paris Bar pro-bono association Initiadroit in secondary schools on European citizenship.

She has, among numerous other publications, co-authored the French chapter of the book Antitrust in Pharmaceutical Markets & Geographical Rules of Origin, co-ed. P. Kobel, P. Këllezi, B. Kilpatrick, Springer, 2017.

Agenda Sessions

  • Recent Developments in ‘Disparagement’ Cases – Key Takeaways for Pharma Companies

    11:45